$2.160
-0.149 (-6.90%)收盤時
XRTX 同業比較
In the context of the broader market, XRTX competes directly with industry leaders such as GELS and PCSA. With a market capitalization of $4.43M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against GELS's N/A and PCSA's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.
XORTX Therapeutics Inc 財務表現
XORTX has shown mixed financial performance, with a recent net income of -808472 USD in Q1 2026 and a forward P/E of 0.9621, suggesting potential for recovery but also indicating ongoing losses.
Financials
FY2026Q1
YoY:
-14.55%
-823.30K
Operating Profit
FY2026Q1
YoY:
+15.72%
-808.47K
Net Income after Tax
FY2026Q2
YoY:
+10.53%
-1.05
EPS - Diluted
FY2026Q2
YoY:
+318.38%
-3.41M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。